SOST and osteoporosis: Importantly, a monoclonal antibody (Romosozumab) that inhibits the Wnt signaling antagonist sclerostin has recently been approved for osteoporosis treatment, as two trials demonstrated that it reduced the rate of vertebral fracture [103].